Related Experiment Video
Updated: Jun 25, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
An association between Dasatinib, elevated left atrial pressure and pleural effusion
Sean Tan1, Diva Baggio2, Kylie Porch2
1Victorian Heart Hospital, Monash Health, Melbourne, Victoria, Australia; Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
Dasatinib use in chronic myeloid leukemia (CML) is linked to pleural effusions (PE) and elevated left atrial pressure (LAP). Echocardiograms can help identify patients at risk for PE, guiding further investigation and management.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) like Dasatinib are crucial for chronic myeloid leukemia (CML) treatment.
- Dasatinib therapy is associated with pleural effusions (PE), a known complication.
- The link between hemodynamic parameters, specifically elevated left atrial pressure (LAP) on transthoracic echocardiogram (TTE), and PE development in CML patients is not well understood.
Purpose of the Study:
- To investigate the association between Dasatinib use, elevated LAP, and PE in CML patients.
- To describe the prevalence of elevated LAP on TTE in CML patients undergoing TKI therapy.
- To identify predictors of elevated LAP in this patient cohort.
Main Methods:
- Retrospective analysis of 71 CML patients who underwent TTE during TKI treatment.
- Descriptive statistics to assess relationships between TKI use, PE, and elevated LAP.
- Multivariate logistic regression to determine factors predicting elevated LAP.
Main Results:
- Dasatinib users showed significantly higher rates of elevated LAP (44%) and PE (39%) compared to Nilotinib and Imatinib users.
- Of 15 patients with PE, 14 (93%) were on Dasatinib.
- Elevated LAP was more common in patients with PE (67%) versus those without (16%).
- Multivariate analysis identified Dasatinib use (OR 33.50) and age (OR 1.12) as significant predictors of elevated LAP.
Conclusions:
- An association exists between Dasatinib, elevated LAP on TTE, and PE in CML patients.
- Elevated LAP may serve as a potential marker for predicting and monitoring PE development.
- Further research is warranted to validate the utility of TTE-derived LAP measurements for PE surveillance in CML patients.
Related Concept Videos
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Heart Failure Drugs: Diuretics
Measurement of Blood Pressure
Antihypertensive Drugs: Potassium-Sparing Diuretics
Pleural Disorders: Types and Brief Description

